Avatrombopag

Generic Name
Avatrombopag
Brand Names
Doptelet 60 Mg Daily Dose Carton, Doptelet
Drug Type
Small Molecule
Chemical Formula
C29H34Cl2N6O3S2
CAS Number
570406-98-3
Unique Ingredient Identifier
3H8GSZ4SQL
Background

Avatrombopag (Doptelet), is an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist which increases platelet number, but not platelet activation , . This decreases the need for blood transfusions .
...

Indication

Indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure .

Associated Conditions
Thrombocytopenia
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly

Not Applicable
Recruiting
Conditions
Severe Aplastic Anemia
Interventions
Drug: Avatrombopag
First Posted Date
2022-06-27
Last Posted Date
2022-06-27
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
80
Registration Number
NCT05433922
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment

First Posted Date
2022-05-19
Last Posted Date
2022-11-10
Lead Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
60
Registration Number
NCT05382013
Locations
🇨🇳

Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Avatrombopag for Chemotherapy-induced Thrombocytopenia

First Posted Date
2022-02-01
Last Posted Date
2023-01-26
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
50
Registration Number
NCT05218226
Locations
🇨🇳

Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

Avatrombopag to Promote Platelet Engraftment After Allo-HSCT

Phase 2
Recruiting
Conditions
Platelet Disorder
Interventions
Drug: Avatrombopag
Other: Supportive care
First Posted Date
2021-12-03
Last Posted Date
2022-12-23
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
20
Registration Number
NCT05143892
Locations
🇨🇳

The first affiliated hospital of Soochow University, Suzhou, Jiangsu, China

Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma

Conditions
Thrombocytopenia
Interventions
Drug: Avatrombopag
First Posted Date
2021-10-21
Last Posted Date
2021-10-21
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
141
Registration Number
NCT05087459
Locations
🇨🇳

Zhongshan hospital, Fudan University, Shanghai, China

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

First Posted Date
2021-08-06
Last Posted Date
2023-11-15
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
52
Registration Number
NCT04993885
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)

First Posted Date
2021-07-02
Last Posted Date
2021-07-02
Lead Sponsor
Shandong University
Target Recruit Count
400
Registration Number
NCT04949009
Locations
🇨🇳

Qilu Hospital, Shandong University, Jinan, Shandong, China

An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP

Active, not recruiting
Conditions
Immune Thrombocytopenia
ITP
Interventions
Drug: Avatrombopag
First Posted Date
2021-06-29
Last Posted Date
2024-10-03
Lead Sponsor
Swedish Orphan Biovitrum
Target Recruit Count
150
Registration Number
NCT04943042
Locations
🇨🇭

Swedish Orphan Biovitrum Research Site 802, Basel, Switzerland

🇪🇸

Swedish Orphan Biovitrum Research Site 606, Oviedo, Spain

🇩🇪

Swedish Orphan Biovitrum Research Site 103, Bad Homburg, Germany

and more 52 locations

Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)

Early Phase 1
Recruiting
Conditions
Thrombocytopenia
Interventions
Drug: Avatrombopag
First Posted Date
2021-06-18
Last Posted Date
2023-08-15
Lead Sponsor
University of Rochester
Target Recruit Count
24
Registration Number
NCT04931849
Locations
🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia

First Posted Date
2021-05-28
Last Posted Date
2021-06-07
Lead Sponsor
Tongji Hospital
Target Recruit Count
150
Registration Number
NCT04906083
Locations
🇨🇳

Department of infectious disease, Tongji Hospital, Wuhan, Hubei, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy